DUBLIN–(BUSINESS WIRE)–The “Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020” report has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.
The report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2014 to 2020.
- Trends in collaborative R&D dealmaking in the biopharma industry since 2014
- Analysis of collaborative R&D deal structure
- Case studies of real-life collaborative R&D deals
- Comprehensive listing of over 5,000 collaborative R&D deals since 2014
- Access to collaborative R&D contract documents
- Key financial benchmarks for headline, upfront, milestone and royalty rates
- The leading collaborative R&D deals by value since 2014
- Most active collaborative R&D dealmakers since 2014
- The leading collaborative R&D partnering resources
There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.
Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.
There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.
In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.
The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all collaborative R&D deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities.
- Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.
- Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.
- Chapter 4 provides a review of the leading collaborative R&D deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
- Chapter 5 provides a review of the top 25 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
- Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2014, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.
- Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2014.
In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.
- In-depth understanding of collaborative R&D deal trends since 2014
- Analysis of the structure of collaborative R&D agreements with numerous real life case studies
- Comprehensive listing of over 5,000 collaborative R&D deals since 2014, together with deal terms, value and press release
- Comprehensive access to actual collaborative R&D contracts entered into by the world’s life science companies
- Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
- Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How do milestone align with clinical stage development phases?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
- 1ST Biotherapeutics
- 3 Sisters Surrogacy
- 3B Medical
- 3B Pharmaceuticals
- 3D Medicines
- 3D Systems
- 3M Drug Delivery Systems
- 4D Molecular Therapeutics
- 4D Pharma
- 10X Genomics
- 14M Genomics
- 22nd Century
- 908 Devices
- A&D Medical
- A*STAR Agency for Science
- Technology and Research
- A*STAR Bioprocessing Technology Institute
- A*STAR Genome Institute of Singapore
- A*STAR’ Institute of Molecular and Cell Biology
- A.I. Squared
- A1M Pharma
- Aarhus University Hospital
- Abbott Laboratories
- Abide Therapeutics
- Abilita Bio
- Ab Initio
- ABL Bio
- Abramson Cancer Center
- Abreos Biosciences
- Academic and Community Cancer Research United
- Academic Drug Discovery Consortium
- Academic Medical Center
- Academy of Nutrition and Dietetics
- Accelerated Cure Project for MS
- Acceleron Pharma
- Access BIO
- Access Health
- ACEA Biosciences
- Acerta Pharma
- Achieve Life Science
- AC Immune
- Acoustic MedSystems
- Acticor Biotech
- Actinium Pharmaceuticals
- ACT Onocology
- Acuity Pharmaceuticals
- Acurx Pharmaceuticals
- Adapsyn Bioscience
- Adapt Analytics
- Adaptate Biotherapeutics
- Adaptive Biotechnologies
- Adaptive Phage Therapeutics
- Adare Pharmaceuticals
- ADB International Group
- ADC Therapeutics
- Addex Therapeutics
- Addiction Institute of Mount Sinai
- Adlai Nortye
- ADL Bionatur Solutions
- ADMA Biologics
- Admera Health
- ADM Tronics
- AdoRx Therapeutics
- Aduro BioTech
- Advaccine Biotechnology
and many, many more!
For more information about this report visit https://www.researchandmarkets.com/r/6pv93n